A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered SNC-102 in Subjects With Drug-Induced Tardive Dyskinesia

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered SNC-102 in Subjects With Drug-Induced Tardive Dyskinesia

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Acamprosate (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Therapeutic Use
  • Sponsors Synchroneuron
  • Most Recent Events

    • 04 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jul 2014 According to a Synchroneuron media release, topline data from this study is expected early in 2015. Approximately half of the subjects have entered or already completed the study.
    • 25 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top